Company news

INmune Bio Inc. news in 2020

INmune Bio Inc.'s news releases, calls and decks from 2020, newest first.

View company

INmune Bio, Inc. Announces First Patient Dosed in Phase 2 Trial of Quellor™ for Pulmonary Complications in COVID-19 Patients

November 8, 2020

INmune Bio, Inc. Announces Third Quarter Results and Provides Business Update

November 4, 2020

INmune Bio, Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on Thursday, November 5

October 28, 2020

INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer’s Drug Discovery

October 4, 2020

INmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support Phase 2 Study of XPro1595 in Patients with Treatment Resistant Depression

September 15, 2020

INmune Bio, Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office Covering INKmune™ Therapy

September 2, 2020

INmune Bio, Inc. Announces FDA Acceptance of IND Application to Evaluate Quellor™ in a Blinded Randomized Phase 2 Trial for Immune Mediated Complications in COVID-19 Patients

August 31, 2020

European Patent Granted Covering INmune Bio’s XPro1595

August 12, 2020

INmune Bio, Inc. Announces Second Quarter 2020 Results and Provides Business Update

August 4, 2020

INmune Bio, Inc. Schedules Conference Call to Report 2020 Second Quarter Financial Results

July 30, 2020

INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Over-Allotment Option

July 19, 2020

INmune Bio, Inc. Prices Public Offering of Common Stock

July 15, 2020

INmune Bio, Inc. Announces Proposed Public Offering of Common Stock

July 14, 2020

INmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflammation in Patients with Alzheimer’s Disease

July 12, 2020

INmune Bio, Inc. to Announce Interim Data from Phase Ib Clinical Study of XPro1595 in Patients with Alzheimer’s Disease Prior to Start of AAIC 2020

July 8, 2020

INmune Bio, Inc. Receives Regulatory Approval from UK MHRA to Initiate Phase I Trial of INKmune in Patients with High-risk MDS

June 10, 2020

INmune Bio, Inc. Announces First Quarter 2020 Results and Provides Business Update

May 13, 2020

INmune Bio Inc’s INB03 Inhibits Cell Migration, Tumor Growth, and Induces Innate Immune Response in Pre-clinical Models of Trastuzumab-Resistant HER2+ Breast Cancer

May 10, 2020

INmune Bio, Inc. to Host First Quarter 2020 Earnings Conference Call

May 5, 2020

INmune Bio Announces Allowance of U.S. Patent Covering Method for Treating Cancer by In Vivo Priming of Natural Killer Cells

April 21, 2020

INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company’s TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19

April 19, 2020

INmune Bio, Inc. Reports Fourth Quarter and Full Year 2019 Results - Drug Pipeline Expands to Now Include Cancer, Alzheimer’s Disease and NASH

March 10, 2020

INmune Bio, Inc. to Present at the 32nd Annual ROTH Conference on March 17

March 4, 2020

INmune Bio, Inc. Schedules Conference Call to Report 2019 Fourth Quarter and Full Year Financial Results

February 26, 2020

INmune Bio, Inc. Awarded $500,000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS

February 9, 2020

INmune Bio, Inc. Announces Data on its Lead Compound Which Highlights The Potential to Lower The Risk of Alzheimer's Disease in Obese Individuals

January 1, 2020

Decks in 2020